Posttransplant recurrence of atypical hemolytic uremic syndrome

Elisabetta Valoti, Marta Alberti, Marina Noris

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Hemolytic uremic syndrome (HUS) is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. It is usually secondary to infections by strains of Escherichia coli (STEC) that produce Shiga-like toxin. In about 10% of patients, no STEC infections are reported. In these cases of atypical HUS (aHUS), mutations in genes encoding proteins of the complement system have been described. Atypical HUS is characterized by poor prognosis and by high risk of posttransplant recurrence which greatly depends on the specific gene mutation involved in the disease. Plasma therapy, eculizumab treatment and, in some cases, combined liver-kidney transplant have been used to prevent and/ or treat posttransplant aHUS recurrences.

Original languageEnglish
Pages (from-to)911-917
Number of pages7
JournalJournal of Nephrology
Volume25
Issue number6
DOIs
Publication statusPublished - Nov 2012

Fingerprint

Shiga Toxins
Recurrence
Escherichia coli Infections
Mutation
Hemolytic-Uremic Syndrome
Hemolytic Anemia
Rare Diseases
Coinfection
Acute Kidney Injury
Thrombocytopenia
Escherichia coli
Transplants
Kidney
Liver
Therapeutics
Genes
Proteins
Atypical Hemolytic Uremic Syndrome
eculizumab

Keywords

  • Atypical hemolytic uremic syndrome (aHUS)
  • Eculizumab
  • Kidney transplant
  • Posttransplant aHUS recurrence

ASJC Scopus subject areas

  • Nephrology

Cite this

Posttransplant recurrence of atypical hemolytic uremic syndrome. / Valoti, Elisabetta; Alberti, Marta; Noris, Marina.

In: Journal of Nephrology, Vol. 25, No. 6, 11.2012, p. 911-917.

Research output: Contribution to journalArticle

Valoti, Elisabetta ; Alberti, Marta ; Noris, Marina. / Posttransplant recurrence of atypical hemolytic uremic syndrome. In: Journal of Nephrology. 2012 ; Vol. 25, No. 6. pp. 911-917.
@article{56eb7459605640b8b2a40973327eeeb7,
title = "Posttransplant recurrence of atypical hemolytic uremic syndrome",
abstract = "Hemolytic uremic syndrome (HUS) is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. It is usually secondary to infections by strains of Escherichia coli (STEC) that produce Shiga-like toxin. In about 10{\%} of patients, no STEC infections are reported. In these cases of atypical HUS (aHUS), mutations in genes encoding proteins of the complement system have been described. Atypical HUS is characterized by poor prognosis and by high risk of posttransplant recurrence which greatly depends on the specific gene mutation involved in the disease. Plasma therapy, eculizumab treatment and, in some cases, combined liver-kidney transplant have been used to prevent and/ or treat posttransplant aHUS recurrences.",
keywords = "Atypical hemolytic uremic syndrome (aHUS), Eculizumab, Kidney transplant, Posttransplant aHUS recurrence",
author = "Elisabetta Valoti and Marta Alberti and Marina Noris",
year = "2012",
month = "11",
doi = "10.5301/jn.5000146",
language = "English",
volume = "25",
pages = "911--917",
journal = "Journal of Nephrology",
issn = "1121-8428",
publisher = "Springer International Publishing",
number = "6",

}

TY - JOUR

T1 - Posttransplant recurrence of atypical hemolytic uremic syndrome

AU - Valoti, Elisabetta

AU - Alberti, Marta

AU - Noris, Marina

PY - 2012/11

Y1 - 2012/11

N2 - Hemolytic uremic syndrome (HUS) is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. It is usually secondary to infections by strains of Escherichia coli (STEC) that produce Shiga-like toxin. In about 10% of patients, no STEC infections are reported. In these cases of atypical HUS (aHUS), mutations in genes encoding proteins of the complement system have been described. Atypical HUS is characterized by poor prognosis and by high risk of posttransplant recurrence which greatly depends on the specific gene mutation involved in the disease. Plasma therapy, eculizumab treatment and, in some cases, combined liver-kidney transplant have been used to prevent and/ or treat posttransplant aHUS recurrences.

AB - Hemolytic uremic syndrome (HUS) is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. It is usually secondary to infections by strains of Escherichia coli (STEC) that produce Shiga-like toxin. In about 10% of patients, no STEC infections are reported. In these cases of atypical HUS (aHUS), mutations in genes encoding proteins of the complement system have been described. Atypical HUS is characterized by poor prognosis and by high risk of posttransplant recurrence which greatly depends on the specific gene mutation involved in the disease. Plasma therapy, eculizumab treatment and, in some cases, combined liver-kidney transplant have been used to prevent and/ or treat posttransplant aHUS recurrences.

KW - Atypical hemolytic uremic syndrome (aHUS)

KW - Eculizumab

KW - Kidney transplant

KW - Posttransplant aHUS recurrence

UR - http://www.scopus.com/inward/record.url?scp=84870588597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870588597&partnerID=8YFLogxK

U2 - 10.5301/jn.5000146

DO - 10.5301/jn.5000146

M3 - Article

C2 - 22760880

AN - SCOPUS:84870588597

VL - 25

SP - 911

EP - 917

JO - Journal of Nephrology

JF - Journal of Nephrology

SN - 1121-8428

IS - 6

ER -